Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: An immunohistochemical analysis

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Rossi, Barbara ^a   Schinzari, Giovanni ^b   MacCauro, Giulio ^a   Scaramuzzo, Laura ^a   Signorelli, Diego ^b   Rosa, Michele A ^c   Fabbriciani, Carlo ^a   Carlo, Barone ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CD31 ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; VASCULOTROPIN; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; ANTIANGIOGENIC THERAPY; ANTIGEN EXPRESSION; ARTICLE; BIOPSY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DENSITY; DIAGNOSTIC TEST; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OUTCOME ASSESSMENT; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STAINING; TUMOR CELL; ADJUVANT THERAPY; BONE TUMOR; DISEASE FREE SURVIVAL; DRUG COMBINATION; FOLLOW UP; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PREDICTION AND FORECASTING; VASCULARIZATION;

ADOLESCENT; ADULT; ANTIGENS, CD31; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHOTREXATE; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77949419636     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-34     Document Type: Article

References (30)

1. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. G Bacci S Ferrari F Bertoni P Picci P Bacchini A Longhi D Donati C Forni L Campanacci M Campanacci, CORR 2001 386 186 196 10.1097/00003086-200105000-00024
2. Osteosarcoma. PA Meyers, Pediatric Bone and Soft Tissue Sarcomas Springer, Pappo A, 1 2006 219 228 full-text
3. Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and non viable tumour. P Picci G Bacci M Campanacci M Gasparini S Pilotti S Cerasoli F Bertoni A Guerra R Capanna U Albisinni S Galletti F Gherlinzoni P Calderoni A Sudanese N Baldini M Bernini N Jaffe, Cancer 1985 56 1515 21 10.1002/1097-0142(19851001)56:7<1515::AID- CNCR2820560707>3.0.CO;2-6 3861228
4. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. M Kaya T Wada T Akatsuka S Kawaguchi S Nagoya M Shindoh F Higashino F Mezawa F Okada S Ishii, Clin Cancer Res 2000 6 2 572 77 10690541
5. Postoperative progression of pulmonary metastasis in osteosarcoma. T Tsunemi S Nagoya M Kaya S Kawaguchi T Wada T Yamashita S Ishii, CORR 2003 407 159 66 10.1097/00003086-200302000-00024
6. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1.702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group Protocols. SS Bielack B Kempf-Bielack G Delling GU Exner S Flege K Helmke R Kotz M Salzer-Kuntschik M Werner W Winkelmann A Zoubek H Jurgens K Winkler, J Clin Oncol 2002 20 776 790 10.1200/JCO.20.3.776 11821461
7. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. M Kaya T Wada S Kawaguchi S Nagoya T Yamashita Y Abe H Hiraga K Isu M Shindoh F Higashino F Okada M Tada S Yamawaki S Ishii, Br J Cancer 2002 86 864 9 10.1038/sj.bjc.6600201 11953816
8. Prognostic relevance of increased angiogenesis in osteosarcoma. M Kreuter R Bieker SS Bielack T Auras H Buerger G Gosheger H Jurgens WE Berdel RM Mesters, Clin Canc Res 2004 10 8531 7 10.1158/1078-0432.CCR-04-0969
9. The effect of neoadjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. MP Link MA Goorin AW Miser AA Green CB Pratt JB Belasco J Pritchard JS Malpas AR Baker JA Kirkpatrick, N Engl J Med 1986 314 1600 6 3520317
10. Treatment of high-grade non-metastatic osteosarcoma (study of 30 cases treated with Scandinavian osteosarcoma protocol XIV and surgery). M Samardziski G Zafiroski C Tolevska B Zafirova-Ivanovska S Kostadinova-Kunovska M Kalikanin-Markovska, Prilozi 2009 29 2 309 24
11. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumour response and the use of granulocyte colony-stimulating factor. T Wada K Isu N Takeda M Usui S Ishii S Yamawaki, Oncology 1996 53 221 7 10.1159/000227564 8643225
12. Markers of angiogenesis and clinical features in patients with sarcoma. S DuBois G Demetri, Cancer 2007 109 5 813 9 Review. 10.1002/cncr.22455 17265525
13. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? ET Ek J Ojaimi Y Kitagawa PF Choong, Int Semin Surg Oncol 2006 21 3 7
14. Hypoxia markers in human osteosarcoma: an exploratory study. H Mizobuchi JM Garca-Castellano S Philips JH Healey R Gorlick, CORR 2008 446 9 2052 9 10.1007/s11999-008-0328-y
15. The endogenous anti-angiogenetic VEGF isoform, VEGF165b inhibits human tumour growth in mice. E Rennel E Waine H Guan Y Schuler W Leenders J Woolard M Sugiono D Gillatt E Kleinerman D Bates S Harper, Br J Cancer 2008 98 7 1250 7 10.1038/sj.bjc.6604309 18349828
16. Tumorigenesis and the angiogenic switch. G Bergers LE Benjamin, Nat Rev Cancer 2003 3 6 401 10 Review. 10.1038/nrc1093 12778130
17. Vascular endothelial growth factor expression in osteosarcoma. RM Charity AF Foukas NS Deshmukh RJ Grimer, CORR 2006 448 193 8 10.1097/01.blo.0000205877. 05093.c9
18. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. K Inoue Y Ozeki T Suganuma Y Sugiura S Takana, Cancer 1997 79 206 13 10.1002/(SICI)1097-0142(19970115)79:2<206::AID-CNCR2>3.0. CO;2-I 9010092
19. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. SI Ishigami S Arii M Niwano T Harada M Mizumoto A Mori H Onodera M Imamura, Br J Cancer 1998 78 1379 84 9823983
20. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. H Maeda Y Chung Y Ogawa S Takatsuka SM Kang M Ogawa T Sawada M Sowa, Cancer 1996 77 858 63 10.1002/(SICI)1097-0142(19960301)77:5<858::AID- CNCR8>3.0.CO;2-A 8608475
21. Microvasculature and VEGF expression in cartilaginous tumors. G Ayala C Liu R Nicosia S Horowitz R Lackman, Hum Pathol 2000 31 341 6 10.1016/S0046-8177(00)80248-8 10746677
22. Diagnostic relevance of the immunohistochemical detection of growth factors in benign and malignant cartilaginous tumors. G Falcone ED Rossi G Maccauro V de Santis MA Rosa A Capelli G Fadda, Appl Immunohistochem Mol Morphol 2006 14 3 334 40 10.1097/00129039-200609000-00013 16932026
23. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. YH Lee T Tokunaga Y Oshika R Suto K Yanagisawa M Tomisawa H Fukuda H Nakano S Abe A Tateishi H Kijima H Yamazaki N Tamaoki Y Ueyama M Nakamura, Eur J Cancer 1999 35 7 1089 93 10.1016/S0959-8049(99)00073-8 10533453
24. CXCR4 and VEGF expression in the primary site and in metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Y Oda H Yamamoto S Tamiya S Matsuda K Tanaka R Yokoyama Y Iwamoto M Tsuneyoshi, Mod Pathol 2006 19 5 738 45 10.1038/modpathol.3800587 16528367
25. The level of vascular endothelial factor as a predictor of a poor prognosis in osteosarcoma. M Kaya T Wada S Nagoya M Sasaki T Matsumura T Yamashita, J Bone Joint Surg Br 2009 91 6 784 8 10.1302/0301-620X.91B6.21853 19483233
26. Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy. Y Huang Z Lin J Zhuang Y Chen J Lin, Onkologie 2008 31 10 535 40 10.1159/000151685 18854653
27. VEGF expression as a prognostic marker in osteosarcoma. J Bajpai M Sharma V Sreenivas R Kumar S Gamnagatti SA Khan S Rastogi A Malhotra S Bakhshi, Pediatr Blood Cancer 2009 53 6 1035 9 10.1002/pbc.22178 19621435
28. A system of staging musculoskeletal neoplasms. WF Enneking, Clin Orthop Relat Res 1986 204 9 24 3456859
29. Management of osteosarcoma. J Whelan B Seddon M Perisoglou, Curr Treat Options Oncol 2006 7 6 444 55 Review. 10.1007/s11864-006-0020-y 17032557
30. Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. M Kaya T Wada S Nagoya S Kawaguchi K Isu T Yamashita, J Bone Joint Surg Br 2004 86 1 143 7 14765882